The Viral Keratitis drugs in development market research report provides comprehensive information on the therapeutics under development for Viral Keratitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Viral Keratitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Viral Keratitis and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Viral Keratitis by seven companies/universities/institutes. The top development phase for Viral Keratitis is preclinical with four drugs in that stage. The Viral Keratitis pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Viral Keratitis pipeline products market are: Zhejiang Raytone Biotechnology, Fox Chase Chemical Diversity Center and Editas Medicine.
The key targets in the Viral Keratitis pipeline products market include Calcineurin, Cholinergic Receptor Muscarinic, and Fibroblast Growth Factor Receptor 1.
The key mechanisms of action in the Viral Keratitis pipeline product include Calcineurin Inhibitor with one drug in Phase II. The Viral Keratitis pipeline products include five routes of administration with the top ROA being Ophthalmic and four key molecule types in the Viral Keratitis pipeline products market including Small Molecule, and Gene Therapy.
Viral Keratitis overview
Viral infection of the cornea is often caused by the herpes simplex virus (HSV) which frequently leaves what is called a ‘dendritic ulcer’. Keratitis is a condition in which the eye’s cornea, the clear dome on the front surface of the eye, becomes inflamed. The condition is often marked by moderate to intense pain and usually involves any of the following symptoms: pain, impaired eyesight, photophobia (light sensitivity), red eye and a ‘gritty’ sensation.
For a complete picture of Viral Keratitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
